focus -WSS

focus

author：fashion 2025-10-01 10:36:24 - browse：5

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： My yearlong odyssey to get my son’s ADHD medication covered

focus

WSS

Research misconduct: Proposed new rules face resistance

Biotech venture capitalists face new demands from investors

My yearlong odyssey to get my son’s ADHD medication covered

The wait for US passports is creating travel purgatory and snarling summer plans

NIH director takes cautious approach to Biden drug pricing priority

Fatty liver disease was alleviated by Lilly’s ‘triple

focus

focus

explore

Tori Bowie and the unacceptable rates of Black maternal death

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Supreme Court strikes down use of affirmative action

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Medicare proposal to cover medical devices draws a mixed reaction

How digital therapeutics firms are pivoting after Pear's bankruptcy

Cancer drug shortages should be causing more outrage

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Hollywood unions extend contract negotiations for actors

Dewpoint Therapeutics lays off staff after losing partnerships

knowledge

'Screen and refer' systems are hurting patients

Fatty liver disease was alleviated by Lilly’s ‘triple

Why doctors need education on FDA device approval process

Medicare Advantage today, explained in one chart

Drug cartel violence flares in western Mexico after vigilante leader's killing

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

focus

focus

explore

leisure time